Australia signs deal with AstraZeneca for possible COVID-19 vaccine By Reuters

Australia signs deal with AstraZeneca for possible COVID-19 vaccine By


© Reuters. FILE PHOTO: Australian Prime Minister Scott Morrison addresses the 74th session of the United Nations General Assembly at U.N. headquarters in New York City, New York, U.S.

By Colin Packham

SYDNEY (Reuters) – Australia has signed a deal with drugmaker AstraZeneca (NYSE:) to secure a potential COVID-19 vaccine, the Prime Minister said on Tuesday, joining a growing list of countries lining up supplies of the drug.

AstraZeneca’s candidate is seen as a frontrunner in the global race to deliver an effective vaccine against the coronavirus that has killed more than 770,000 people and infected nearly 22 million, according to a Reuters tally.

With several countries moving to secure supplies that some fear may lead to a global shortage, Australia said it had signed a letter of intent with AstraZeneca to produce and distribute enough doses for its population.

“Under this deal we have secured early access for every Australian,” Prime Minister Scott Morrison said in an emailed statement.

“If this vaccine proves successful we will manufacture and supply vaccines straight away under our own steam and make it free for 25 million Australians.”

Countries around the world are looking to secure supplies of Astrazeneca (LON:)’s potential vaccine. Most recently Argentina and Mexico said last week they would produce it for much of Latin America.

Morrison, however, cautioned that while AstraZeneca’s candidate is showing early promise, there was no guarantee it would materialise as an effective tool in preventing COVID-19.

Once heralded as a global leader in combating COVID-19, Australia has seen a surge of new infections in the past month. Yet its tally of nearly 24,000 cases and 438 deaths is still far fewer than many other developed nations.

Morrison said Australia is also committed to ensuring early access to a vaccine for Pacific countries, which are increasingly wooed by China, much to Canberra’s concern.

Earlier, Australia’s biggest biotech company CSL (OTC:) Ltd said it was in talks with AstraZeneca to determine if the potential COVID-19 vaccine being developed by the British drugmaker could be manufactured locally.

In addition to pressing ahead with securing a potential vaccine, Australia said it had also signed a A$24.7 million ($17.9 million) deal with U.S. medical technology company Becton Dickinson (NYSE:) to buy 100 million needles and syringes.

($1 = 1.3824 Australian dollars)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME